Development of Advanced Sterile Drug Delivery Manufacturing Capabilities for Injectable and Ophthalmic Products in Saudi Arabia

Saudi Arabia's pharmaceutical localisation agenda is moving beyond import substitution and secondary packaging towards technically independent manufacture. Sterile injectables and ophthalmic products are decisive test cases, because uninterrupted supply depends on simultaneous mastery of contamination control, sterile utilities, terminal sterilisation or aseptic processing, specialised packaging, analytical release and a mature pharmaceutical quality system. This integrative review synthesises Saudi supply-side evidence with current normative requirements from the Saudi Food and Drug Authority (SFDA), the World Health Organization, the European Commission, the United States Food and Drug Administration and the International Council for Harmonisation. The Saudi evidence is consistent across independent datasets. In a survey of 350 stakeholders conducted between November 2024 and February 2025, 73.0% of supply-chain respondents agreed that disruption significantly affects the availability of sterile injectable products, and 65.7% of healthcare professionals reported adverse effects on patient care. A separate survey of 379 personnel within the Ministry of Health supply chain found that 90.0% had experienced shortages of essential medicines or supplies, with 48.5% identifying inadequate planning, forecasting and procurement as the leading cause. An analysis of the SFDA formulary covering items available between 2010 and 2019 attributed 22.55% of registered medicines to Saudi manufacture. The review proposes a capability-based architecture integrating terminal sterilisation wherever scientifically feasible, barrier-enabled aseptic filling, ready-to-use containers, lyophilisation, blow-fill-seal ophthalmic platforms, deterministic container-closure integrity testing and digital quality systems. Localisation should be measured by qualified releasable capacity, process robustness and reduction in shortage exposure rather than by the number of products packaged domestically.